CN108424964A - A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 and its application - Google Patents
A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 and its application Download PDFInfo
- Publication number
- CN108424964A CN108424964A CN201810372419.8A CN201810372419A CN108424964A CN 108424964 A CN108424964 A CN 108424964A CN 201810372419 A CN201810372419 A CN 201810372419A CN 108424964 A CN108424964 A CN 108424964A
- Authority
- CN
- China
- Prior art keywords
- pancreas
- cancer
- prognosis
- clec18b
- lnc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to cancer of pancreas prognosis molecule marker non-coding RNA Lnc CLEC18B 3 and its applications, it can effectively solve the problems, such as to prepare the kit for predicting Pancreas cancer patients prognosis, a kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc CLEC18B 3, its transcript length is more than 200 nucleotide, and sequence is SEQ NO:1；The cancer of pancreas prognosis real-time fluorescence quantitative PCR detection kit includes the specific primer for the kit expression for detecting Pancreas cancer patients prognosis being placed in box body, and primer sequence is SEQ No：2 and 3, the primer sequence of reference gene TUBA1A expression, primer sequence are SEQ No：4,5 and RNA is extracted from Pancreatic Adenocarcinoma, and carry out the reagent of reverse transcription and quantitative fluorescent PCR.Lnc CLEC18B 3 of the present invention are a kind of newfound non-coding RNAs, it can be effectively used for preparing the kit of Pancreas cancer patients prognosis, molecular marker new as cancer of pancreas prognosis non-coding RNA Lnc CLEC18B 3, cancer of pancreas prognosis can be predicted in time, and Pancreas cancer patients are treated in time, extend the survival of patients time, improves survival rate.
Description
Technical field
The present invention relates to oncomolecularbiology, especially a kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-
CLEC18B-3 and its application.
Background technology
Cancer of pancreas is one of highest tumour of grade malignancy, and incidence of occult, progress is rapid, Resection Rate is low, putting
Therapeutic effect is bad, poor prognosis, and overall 5 years survival rates account for the 13rd in global cancer morbidity, come all less than 5%
The 4th of the malignant tumour cause of death.Have there is lymph in most of Pancreas cancer patients when often making a definite diagnosis or blood operating moves, from
And lose the chance of radical surgery treatment.The main reason for Pancreas cancer patients are dead is tumour early stage local challenge to occur
Or DISTANT METASTASES IN, and restrict the principal element of patient's prognosis.The invasion metastasis of cancer of pancreas is still not clear at present, understands pancreas
The malignant behaviors mechanism of gland cancer, and intervening measure appropriate is given, for improving the clinical diagnosis and treatment water of cancer of pancreas
It puts down and the prognosis for improving patient is of great practical significance.Currently, clinically there are no ideal molecular indexes to comment
The risk estimated prognosis and shifted.Therefore, it is current urgent problem to find new prognosis biomarker.
Long-chain non-coding RNA be a kind of transcript length be more than 200nt, non-coding protein RNA.Long-chain non-coding
RNA participates in the different phase of the various vital movements of cell, the every single step reaction being almost related in life cycle, such as gene and turns
Record, the montage of mRNA, RNA decays and translation etc..In some complicated diseases, relevant signal is typically derived from genome
Non-coding region, more and more researchs also indicate that the unconventionality expression of long-chain non-coding RNA is associated with mankind's major disease.
In addition, more and more results of study find that numerous long-chain non-coding RNAs have participated in the occurrence and development of cancer.Currently,
Research confirms the long-chain non-coding RNA of unconventionality expression, all exists in numerous malignant tumours, the notable up-regulation having, what is had is notable
It lowers.Wherein representative research is found in breast cancer, liver cancer and prostate cancer.The research of long-chain non-coding RNA has
There is critically important researching value, especially in clinical research and on drug development, it can be not only the research of numerous diseases,
Including tumour and angiocardiopathy and other very refractory disease provides new foundation and target spot at present, and help
Complicated life regulation process is recognized in people.It will be the center of gravity in future life science field to the research of long-chain non-coding RNA
With focus, contribute to the pathogenesis for more thoroughly understanding mankind's major disease, is carried for the early diagnosis and treatment in time of disease
For biomarker and corresponding drug target.Lnc-CLEC18B-3 is a kind of newfound non-coding RNA, transcription
This length is more than 200 nucleotide.Currently, non-coding RNA Lnc-CLEC18B-3 is sent out in normal cell development or tumour
The important function played during exhibition is also in further research.Whether Lnc-CLEC18B-3 can swell as a kind of new
Tumor markers reagent preparation and kit are applied to prediction Pancreas cancer patients prognosis so far there are no open report.
Invention content
For the above situation, to overcome the defect of the prior art, the purpose of the present invention to be just to provide a kind of cancer of pancreas prognosis
Molecular marker non-coding RNA Lnc-CLEC18B-3 and its application can effectively solve to prepare prediction Pancreas cancer patients prognosis
The problem of kit.
The technical solution that the present invention solves is a kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-
3, transcript length is more than 200 nucleotide, and sequence is SEQ NO:1；
The cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 is preparing cancer of pancreas prognosis real time fluorescent quantitative
Application in PCR detection kit；
The cancer of pancreas prognosis real-time fluorescence quantitative PCR detection kit includes being placed in suffering from for detecting cancer of pancreas in box body
The specific primer of the kit expression of person's prognosis, primer sequence are SEQ No：2 and 3, the primer of reference gene TUBA1A expression
Sequence, primer sequence are SEQ No：4,5 and RNA is extracted from Pancreatic Adenocarcinoma, and carry out reverse transcription and quantitative fluorescent PCR
Reagent.
Lnc-CLEC18B-3 of the present invention is a kind of newfound non-coding RNA, and it is pre- to can be effectively used for preparation Pancreas cancer patients
Kit afterwards, molecular marker new as cancer of pancreas prognosis non-coding RNA Lnc-CLEC18B-3, can predict pancreas in time
Cancer prognosis, and Pancreas cancer patients are treated in time, extend the survival of patients time, improves survival rate, be in cancer of pancreas prognosis
A big innovation, economic and social benefit is huge.
Description of the drawings
Fig. 1 is that real-time fluorescence quantitative PCR of the present invention analyzes expression of the Lnc-CLEC18B-3 in normal structure and cancer of pancreas
Disparity map.
Fig. 2 is the Lnc- that the present invention analyzes the influence prognosis survivorship curve of Pancreas cancer patients in Pancreatic Adenocarcinoma source
CLEC18B-3 expresses high-low graph.
Specific implementation mode
It elaborates to the specific implementation mode of the present invention below in conjunction with concrete condition.
In specific implementation, a kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 is the present invention
A kind of newfound non-coding RNA Lnc-CLEC18B-3 molecular markers, are long-chain non-coding RNA, and transcript length is big
In 200 nucleotide, which is classified as SEQ No：1：
SEQ NO:1
GCGGCGGGCCCGGATCTTCGCCACCGCCGTCATTTGTGGGCGGAGAAAGGGCTGGAGAAAGGCGGGAATCGCC
CCTCGTCCCTCGCCGTGCGTTTCCCTGGACTTAAGGGCCGAAGGGACACCGGCGACTTGACCTCCTGGTATTGGCCT
GTACCGTCACCTGCAGAGGCTTTTCGCCTCAATTCCTTCCCAGCACCCTCCCCCCGCCACCCCCCCAAAGTAAATAG
TTGACAGTTTACTTTTCTACCACCCGGAAGAAGTTCACTTTTGCTTCAGGTCAAAATCCTCCGCGATTTCTGAGAGG
AACTTTAAATCTCTAACATAAGAGCACGCTTTTAATGTAATTTGATTGCAGGGAGAGGCTCCTCCGTGCTCCTGAGA
GGCCGAACACAGGGTCGCCAGCACAGCTTACTGCTCGG 419
The cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 is preparing cancer of pancreas prognosis real time fluorescent quantitative
Application in PCR detection kit；
The cancer of pancreas prognosis real-time fluorescence quantitative PCR detection kit includes being placed in suffering from for detecting cancer of pancreas in box body
The specific primer of the kit expression of person's prognosis, primer sequence are SEQ No：2 and 3, the primer of reference gene TUBA1A expression
Sequence, primer sequence are SEQ No：4,5 and RNA is extracted from Pancreatic Adenocarcinoma, and carry out reverse transcription and quantitative fluorescent PCR
Reagent, wherein：
SEQ NO:2
ATCTTCGCCACCGCCGTC
SEQ NO:3
CAGTAAGCTGTGCTGGCGA
SEQ NO:4
ggagctctactgcctggaac
SEQ NO:5
agagaacctgcggcacatag
The kit of Lnc-CLEC18B-3 expression quantity is that real-time fluorescence determines PCR detection reagents in the detection Pancreatic Adenocarcinoma
Box.
The real-time fluorescence quantitative PCR detection kit includes the specific primer for carrying out real-time fluorescence quantitative PCR, packet
The specific primer for detecting Lnc-CLEC18B-3 expression is included, primer sequence is SEQ NO:2,3 and reference gene
The primer sequence of TUBA1A expression, primer sequence are SEQ NO: 4、5.
The real-time fluorescence quantitative PCR detection kit also contains in addition to the primer of Lnc-CLEC18B-3 from pancreas
RNA is extracted in cancerous tissue and carries out all reagents of reverse transcription and quantitative fluorescent PCR.Including：
(1) the extracted total RNA agents useful for same from the tumour of cancer of pancreas or normal control tissue, including Trizol liquid, chloroform, isopropyl
Alcohol inhibits RNA degradations solvent, 75% ethyl alcohol, DEPC water；
(2) it is cDNA agents useful for same by Lnc-CLEC18B-3 reverse transcriptions by template of total serum IgE, including reverse transcription reaction buffer solution,
Containing containing Mg2+Triphosphoric acid base deoxynucleotide dNTP, reverse transcriptase M-MLV and random primer and Oligo dT primers
Mixture；
(3) by cDNA real-time quantitative PCR agents useful for same, including Lnc-CLEC18B-3 real-time fluorescence quantitative PCRs specific primer,
TUBA1A internal references Specific PCR primers, real time fluorescent quantitative SYBR dyestuffs, the water without RNA enzyme.
The present invention has found the Lnc-CLEC18B-3 in Pancreatic Adenocarcinoma source by quantitative fluorescent PCR and survivorship curve analysis
Related to the survival rate of patient, content is higher, and survival rate is higher.This method is to predict that the prognosis life cycle analysis of Pancreas cancer patients carries
Strong technical support has been supplied, the postoperative life quality of Pancreas cancer patients is helped to improve, has worked out aftertreatment scheme, has been improved
Survival rate has far-reaching clinical meaning.And through site test, achieve very satisfied advantageous effects, relevant information
It is as follows：
Embodiment 1
The reagent for preparing detection Lnc-CLEC18B-3 expression quantity is used to prepare the kit of Pancreas cancer patients prognosis (for 30 times
Reaction)
1. Trizo l20ml
2. inhibiting RNA degradation solvents 40ml
3. chloroform 80ml
4. isopropanol 80ml
5. DEPC water 10ml
6. the 100 μ l of mixture of 10 × random primer and Oligo dT primers
7. 5 × reverse transcription reaction buffer solution, 150 μ l
8. 10mM contains Mg2+100 μ l of triphosphoric acid base deoxynucleotide dNTP
9. 50 μ l of 200U/ μ l M-MLV reverse transcriptases
10. SYBR Green qPCR Mix 500μl
11. 3 μM of target gene Lnc-CLEC18B-3 specific primers（Its sequence such as SEQ NO:2, shown in 3） 50μl
12. 3 μM of reference gene TUBA1A specific primers（Its sequence such as SEQ NO:4, shown in 5） 50μl
The detection of 2 tissue samples Lnc-CLEC18B-3 of embodiment
1, cancer of pancreas to be measured or normal control tissue are collected, after physiological saline cleans up, is put into and fills inhibition RNA degradation solvents
Cryopreservation tube in, put spare to -80 DEG C of refrigerators.
2, the extracting of RNA in organizing：
（1）Liquid nitrogen is first added in mortar, then tissue is cut into small pieces and is clayed into power in liquid nitrogen, is taken with the spoon of Liquid nitrogen precooler
100mg organizes powder to be added in the EP pipes for the Trizol liquid for having filled 1ml.Organize total powder volume no more than Trizol used
The 10% of volume is sufficiently mixed uniformly.
（2）5 minutes are placed at room temperature for, the chloroform of 200 μ L is then added, EP is covered tightly and manages and acutely sway 0.5 minute.12000
Rev/min centrifugation 10 minutes.
（3）Take upper strata aqueous phase in a new EP pipes（The intermediate beds of precipitation and subnatant are not mixed into）, 500 μ L isopropyls are added
Alcohol mildly overturns mixing.10 minutes are placed at room temperature for, 12000 revs/min centrifuge 10 minutes.
（4）Liquid is carefully discarded supernatant, is added 75% ethyl alcohol of 1ml, vortex mixing, 12000 revs/min of centrifugations 5 at 4 DEG C
Minute.Repetitive operation is primary.
（5）Discard supernatant liquid（Residual liquid is removed as possible）, room temperature or vacuum drying 5~10 minutes（It is careful not to do
It is dry excessive, it otherwise can reduce the solubility of RNA）.RNA is dissolved with 50 μ L DEPC processed water.
（6）RNA concentration mensurations：It is measured with nucleic acid concentration analyzer, inhales 1 μ L RNA samples and add to sample well, according to
Reading directly determines the concentration of RNA.The OD260/OD280 ratios of the measurement of nucleic acid concentration analyzer, ratio is between 1.8-2.0
Think that RNA purity is fine.Finally, it is spare to be stored in -80 DEG C of refrigerators by RNA.
3, the reverse transcription of Lnc-CLEC18B-3 RNA：It is tried using the reverse transcription of the green skies Bioisystech Co., Ltd in Shanghai
Agent box（D7170S）.It is as follows.
（1）Remove genomic DNA：Template Total RNA, 5 × gDNA Eraser Buffer are thawed on ice, 5 ×
RT Buffer, 10 × RT Primer Mix, DEPC-treated Water are in (15-25 DEG C) defrosting of room temperature, after defrosting rapidly
It is placed on ice.Using it is preceding by each solution mixing and it is of short duration centrifugation so that all liq is settled down to tube bottom.The denaturation of RNA,
RNA sample thermal denaturation under the conditions of 65 DEG C is immediately placed in ice water cooling after 5 minutes.According to the form below ingredient is in preparation reaction on ice
Then mixed liquor is dispensed into each reaction tube, is eventually adding RNA sample again.
（2）In PCR instrument or in water-bath, 37 DEG C are incubated 2 minutes.Be immediately placed in place on ice it is spare.
（3）Reverse transcription system is prepared：Reaction solution preparation is carried out on ice, and reverse transcription reaction is carried out immediately after soft mixing.
Mixed liquor is prepared according to the reverse transcription reaction system of following table.
（4）42 DEG C are incubated 60 minutes to carry out reverse transcription reaction, after subsequent 80 DEG C are incubated 10 minutes inactivation reverse transcriptases
It is put on ice.For the template of secondary structure complexity or high GC content, reverse transcription temperature can be improved to 50 DEG C, reversed with enhancing
Record efficiency.
（5）Obtained cDNA can immediately or -80 DEG C freeze after be used for follow-up real-time fluorescence quantitative PCR, cDNA preferably avoided
More multigelations.
4, real-time quantitative PCR is carried out using the specific primer of Lnc-CLEC18B-3：Specific primer is in raw work biology work
Journey（Shanghai）Limited liability company synthesizes, and includes the specific primer for detecting Lnc-CLEC18B-3 expression, and primer sequence is
SEQ NO:2, the primer sequence that 3 and reference gene TUBA1A is expressed, primer sequence are SEQ NO: 4、5.Real-time quantitative
The other reagents of PCR utilize the BeyoFast SYBR Green qPCR Mix (2 of the green skies Bioisystech Co., Ltd in Shanghai
×), it is as follows：
（1）Melt and mixing PCR reacts required various solution, BeyoFast SYBR Green qPCR Mix melt completely
And mixing is placed in ice chest.
（2）PCR reaction systems (by taking 96 orifice plates as an example) are set on ice bath：
(3) the usually amount of DNA profiling with 1-10ng cDNA is with reference to dosage, and final concentration of 0.2-0.5 μM of primer when can be obtained
Good detection result is obtained, the final concentration of primer also can be according to circumstances adjusted.If it is necessary, gradient dilution can be carried out to template,
With the template usage amount that determination is best.When reverse transcription PCR cDNA obtained by the reaction is directly as template, additive amount does not exceed
PCR reacts the 10% of total volume.The recommendation response system of 96 orifice plates is 20 μ l, can also in proportion be expanded according to actual experiment demand
Big or diminution reaction system.
(4) mixing or slight Vortex mixings are gently blown and beaten with pipettor, room temperature centrifuges the several seconds, liquid is made to accumulate in pipe
Bottom.
(5) the PCR reaction tubes set or PCR reaction plates are placed on fluorescence quantitative PCR instrument, start PCR reactions.
(6) PCR response procedures：The pre-degeneration that template is carried out before real-time fluorescence quantitative PCR reacts, is typically set at 95 DEG C
2 minutes.Using following PCR programs, this program is by taking ABI 7900HT fluorescence quantitative PCR instruments as an example：
A. pre-degeneration：95℃ 2min
B. it is denaturalized：95℃ 15sec
C. annealing/extension：60℃ 15-30sec
D. step b and step c is repeated, in total 40 cycles
E. melting curve analysis (optional)：95℃ 15sec, 60℃ 15sec, 95℃ 15sec
F. the software analysis result for using fluorescence quantitative PCR instrument to provide
Three-step approach only need to after annealing/extension plus 72 DEG C of 30sec of a step, then repeat step b, c and it is increased the step for it is total
40 cycles.
5, the data analysis of Lnc-CLEC18B-3 expression quantity：This experimental data is included in 60 Pancreas cancer patients and its normal
Control tissue.The interpretation of result of real-time quantitative PCR uses relative quantitation method, that is, 2^-△△CtMethod.It is specific as follows：It first, will be primary
All gene C t values of experiment are put in order, later with the Ct values of the target gene Lnc-CLEC18B-3 in each group of tumor sample
The Ct values of itself reference gene TUBA1A are subtracted, obtained number is exactly △ Ct；Changing formula into is exactly：△Ct=Ct（Target gene
Lnc-CLEC18B-3）-Ct（Reference gene TUBA1A）；Then, by each group of each target gene of tumor sample Lnc-
The △ Ct of CLEC18B-3 are calculated.Normal control tissue group sample is subtracted with the △ Ct of tumor tissues sample in this experiment
△ Ct, and opposite number is taken to all results simultaneously, the result which obtains is exactly-△ △ Ct.Finally, p- △ △ Ct into
The power operation of row 2, i.e. 2^-△△CtJust show that the multiple of expression quantity changes.In triplicate, it is counted using nonparametric t- inspections
Analysis.The expression quantity of Lnc-CLEC18B-3 is higher than normal control in the tumor tissues of cancer of pancreas（See Fig. 1）, difference, which has, to be counted
Difference (p＜ 0.05).
6, by 60 Pancreas cancer patients follow-up statistics being included in above-mentioned experiment, including patient's First episode
Time, treatment, recurrence status and death time etc., follow up time are at least 12 months.In selected Pancreas cancer patients
In, the expression value for choosing fluorescence real-time quantitative PCR analysis is reference standard, and the corresponding normal structure of acquired results is compared
Compared with.Lnc-CLEC18B-3 expression is defined as Lnc-CLEC18B-3 high expression higher than the patient of normal control tissue in tumor tissues
Group, remaining is low expression group.By Kaplan-Meier survival analysis, Lnc-CLEC18B-3 high expresses the life cycle ratio of patient
The patient of Lnc-CLEC18B-3 low expression groups is substantially reduced, and prognosis is worse（See Fig. 2）, difference have it is statistically significant (p＜
0.05).Therefore, Lnc-CLEC18B-3 can be used as the specificity molecular marker of Pancreas cancer patients prognosis.
By above it should be apparent that the invention discloses a kind of new cancer of pancreas prognosis molecule marker non-codings
RNA Lnc-CLEC18B-3 are used to prepare the kit of Pancreas cancer patients, the Lnc- tissue-derived by detecting pancreatic tumour
The kit of CLEC18B-3.Lnc-CIT-1 up-regulated expressions in cancer of pancreas, height expression Lnc-CLEC18B-3 are confirmed by research
Pancreas cancer patients, overall survival is worse.Therefore, by detecting Lnc-CLEC18B-3 in Pancreas cancer patients tumor tissues
Expression, Pancreas cancer patients can be made prognosis inspection diagnosis, accuracy rate is up to 96% or more, and is treated in time,
Survival and life quality are improved, there is far-reaching clinical application significance and application value, economic and social benefit
It is huge.
Sequence table
<110>The first affiliated hospital of Zhengzhou University
<120>A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 and its application
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 419
<212> DNA
<213> Homo sapiens
<400> 1
gcggcgggcc cggatcttcg ccaccgccgt catttgtggg cggagaaagg gctggagaaa 60
ggcgggaatc gcccctcgtc cctcgccgtg cgtttccctg gacttaaggg ccgaagggac 120
accggcgact tgacctcctg gtattggcct gtaccgtcac ctgcagaggc ttttcgcctc 180
aattccttcc cagcaccctc cccccgccac ccccccaaag taaatagttg acagtttact 240
tttctaccac ccggaagaag ttcacttttg cttcaggtca aaatcctccg cgatttctga 300
gaggaacttt aaatctctaa cataagagca cgcttttaat gtaatttgat tgcagggaga 360
ggctcctccg tgctcctgag aggccgaaca cagggtcgcc agcacagctt actgctcgg 419
<210> 2
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 2
atcttcgcca ccgccgtc 18
<210> 3
<211> 19
<212> DNA
<213> Artificial Sequence
<400> 3
cagtaagctg tgctggcga 19
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 4
ggagctctac tgcctggaac 20
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 5
ggagctctac tgcctggaac 20
Claims (3)
1. a kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 is long-chain non-coding RNA, transcription
This length is more than 200 nucleotide, which is classified as SEQ No：1.
2. cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 described in claim 1 is preparing cancer of pancreas
Application in prognosis real-time fluorescence quantitative PCR detection kit.
3. the cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 described in claim 2 is preparing cancer of pancreas
Application in prognosis real-time fluorescence quantitative PCR detection kit, which is characterized in that the cancer of pancreas prognosis real time fluorescent quantitative
PCR detection kit includes the specific primer for the kit expression for detecting Pancreas cancer patients prognosis being placed in box body,
Primer sequence is SEQ No：2 and 3, the primer sequence of reference gene TUBA1A expression, primer sequence are SEQ No：4 and 5 and from
RNA is extracted in pancreatic tissue, and carries out the reagent of reverse transcription and quantitative fluorescent PCR.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810372419.8A CN108424964A (en) | 2018-04-24 | 2018-04-24 | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810372419.8A CN108424964A (en) | 2018-04-24 | 2018-04-24 | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108424964A true CN108424964A (en) | 2018-08-21 |
Family
ID=63161597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810372419.8A Pending CN108424964A (en) | 2018-04-24 | 2018-04-24 | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108424964A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106350600A (en) * | 2016-11-04 | 2017-01-25 | 叶伟亮 | Application of LOC80054 in diagnosis or prognosis of pancreatic cancer |
| CN106399569A (en) * | 2016-12-01 | 2017-02-15 | 北京致成生物医学科技有限公司 | Application of C2lorf82 in preparation of pancreatic cancer prognosis evaluation products |
-
2018
- 2018-04-24 CN CN201810372419.8A patent/CN108424964A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106350600A (en) * | 2016-11-04 | 2017-01-25 | 叶伟亮 | Application of LOC80054 in diagnosis or prognosis of pancreatic cancer |
| CN106399569A (en) * | 2016-12-01 | 2017-02-15 | 北京致成生物医学科技有限公司 | Application of C2lorf82 in preparation of pancreatic cancer prognosis evaluation products |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180245162A1 (en) | Fusion genes associated with progressive prostate cancer | |
| EP3571322B9 (en) | Molecular subtyping, prognosis, and treatment of bladder cancer | |
| WO2011079846A2 (en) | Mrna classification of thyroid follicular neoplasia | |
| CN109680064B (en) | Application of YTHDF2 gene in diagnosis, prevention and treatment of urothelial cancer | |
| CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
| CN108707664A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COX19-2 and its application | |
| CN108949976A (en) | Purposes of the C12orf70 and/or C17orf107 gene in cancer of pancreas testing product | |
| CN108424965A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CRYBA4-23 and its application | |
| CN108546760A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COL20A1-2 and its application | |
| CN108728547A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00158 | |
| CN108424964A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CLEC18B-3 and its application | |
| CN108753978A (en) | Application, kit and the detection method of lung cancer for prognosis novel molecular marker non-coding RNA LINC01124 | |
| CN108753977A (en) | Application, kit and the detection method of lung cancer for prognosis novel molecular marker non-coding RNA LINC00958 | |
| CN109251927A (en) | A kind of application of the long-chain non-coding RNA and combinations thereof in diagnosis/treatment cholangiocarcinoma | |
| CN108998519A (en) | Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis | |
| CN109266742A (en) | Predict the biomarker long-chain non-coding RNA LINC02456 and kit of colon cancer prognosis | |
| CN108546759A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CPM-2 and its application | |
| KR102339206B1 (en) | MICRO-RNA signature for the prediction of hepatic dysfunction | |
| CN109666742B (en) | Application of novel gastric cancer marker gene circ-CC2D1A | |
| CN108796087A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00668 | |
| CN108424966A (en) | A kind of gastric cancer prognosis molecule marker non-coding RNA Lnc-CIT-1 and its application | |
| CN109022577A (en) | Predict the biomarker long-chain non-coding RNA LINC01366 and kit of lung cancer for prognosis | |
| CN108642184A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00200 | |
| CN108642183A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00671 | |
| CN108546758A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-DCAF1-1 and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180821 |
|
| WD01 | Invention patent application deemed withdrawn after publication |